Article ; Online: A novel large intragenic DPYD deletion causing dihydropyrimidine dehydrogenase deficiency: a case report.
2024 Volume 17, Issue 1, Page(s) 78
Abstract: Background: Dihydropyrimidine dehydrogenase (DPD), is the initial and rate-limiting enzyme in the catabolic pathway of pyrimidines. Deleterious variants in the DPYD gene cause DPD deficiency, a rare autosomal recessive disorder. The clinical spectrum of ...
| Abstract | Background: Dihydropyrimidine dehydrogenase (DPD), is the initial and rate-limiting enzyme in the catabolic pathway of pyrimidines. Deleterious variants in the DPYD gene cause DPD deficiency, a rare autosomal recessive disorder. The clinical spectrum of affected individuals is wide ranging from asymptomatic to severely affected patients presenting with intellectual disability, motor retardation, developmental delay and seizures. DPD is also important as the main enzyme in the catabolism of 5-fluorouracil (5-FU) which is extensively used as a chemotherapeutic agent. Even in the absence of clinical symptoms, individuals with either complete or partial DPD deficiency face a high risk of severe and even fatal fluoropyrimidine-associated toxicity. The identification of causative genetic variants in DPYD is therefore gaining increasing attention due to their potential use as predictive markers of fluoropyrimidine toxicity. Methods: A male infant patient displaying biochemical features of DPD deficiency was investigated by clinical exome sequencing. Bioinformatics tools were used for data analysis and results were confirmed by MLPA and Sanger sequencing. Results: A novel intragenic deletion of 71.2 kb in the DPYD gene was identified in homozygosity. The deletion, DPYD(NM_000110.4):c.850 + 23455_1128 + 8811del, eliminates exons 9 and 10 and may have resulted from a non-homologous end-joining event, as suggested by in silico analysis. Conclusions: The study expands the spectrum of DPYD variants associated with DPD deficiency. Furthermore, it raises the concern that patients at risk for fluoropyrimidine toxicity due to DPYD deletions could be missed during pre-treatment genetic testing for the currently recommended single nucleotide polymorphisms. |
|---|---|
| MeSH term(s) | Infant ; Humans ; Male ; Dihydropyrimidine Dehydrogenase Deficiency/genetics ; Dihydropyrimidine Dehydrogenase Deficiency/complications ; Dihydropyrimidine Dehydrogenase Deficiency/drug therapy ; Dihydrouracil Dehydrogenase (NADP)/genetics ; Dihydrouracil Dehydrogenase (NADP)/metabolism ; Antimetabolites, Antineoplastic/adverse effects ; Fluorouracil/adverse effects ; Genetic Testing |
| Chemical Substances | Dihydrouracil Dehydrogenase (NADP) (EC 1.3.1.2) ; Antimetabolites, Antineoplastic ; Fluorouracil (U3P01618RT) |
| Language | English |
| Publishing date | 2024-03-25 |
| Publishing country | England |
| Document type | Case Reports ; Journal Article |
| ZDB-ID | 2411865-5 |
| ISSN | 1755-8794 ; 1755-8794 |
| ISSN (online) | 1755-8794 |
| ISSN | 1755-8794 |
| DOI | 10.1186/s12920-024-01846-2 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.